The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients With Cervical Carcinoma
Abstract
Human papillomavirus type 16 (HPV16)-encoded E7 oncoprotein is constitutively expressed in cervical carcinoma cells and is required for cellular transformation to be maintained. The E7 protein, therefore, forms an attractive target for T-cell-mediated immune intervention to prevent or treat HPV16+ tumors. The authors performed a peptide-based phase I/II vaccination trial to induce anti-tumor immune responses in patients with recurrent or residual cervical carcinoma. Fifteen HLA-A*0201+ patients with HPV16+ cervical carcinoma received vaccinations with synthetic peptides representing 2 HPV16 E7-encoded, HLA-A*0201-restricted cytotoxic T lymphocyte epitopes and a pan-HLA-DR-binding T-helper epitope, PADRE, in adjuvant. No signs of toxicity were observed. Two patients had stable disease for more than 1 year after vaccination, 3 patients died of the disease during or shortly after the vaccination period, and 10 patients maintained progressive cervical carcinoma. Specific immune responses directed against the vaccine components were analyzed in peripheral blood samples. No cytotoxic T lymphocyte responses against the HPV16 E7 peptides were detectable. After vaccination, strong PADRE helper peptide-specific proliferation was detected in 4 of 12 patients. In conclusion, peptide vaccination with 2 HPV16 E7 cytotoxic T lymphocyte epitopes and a universal T helper epitope is well tolerated by patients with advanced cervical carcinoma. Despite a reduction of in vitro cytolytic or proliferative recall responses to some, but not all, conventional antigens in this patient group, peptide-specific proliferative responses were induced in 4 patients. Based on the current study, it is now feasible to perform peptide vaccination in earlier stages of HPV16-induced cervical disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“A newly developed approach based on T-cell receptor interaction with antigenic complexes in the form of tetramers (41) may allow detection of low numbers of (viral) peptide-specific CTLs.”
MethodVaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862 · cited 1×
“The use of dendritic cells, pulsed ex vivo with peptides, protein, or tumor cell lysate and reinfused into patients with metastatic melanoma or with follicular B-cell lymphoma, resulted in concomitant clinical and T-cell responses (37,38).”
BackgroundVaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., Engleman, E. G., & Levy, R. (1996) · Nature Medicine · doi:10.1038/nm0196-52 · Cited by 1,804
Cited by
Knutson, K. L., Schiffman, K., & Disis, M. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11752 · Cited by 439
Zwaveling, S., Mota, S. C. F., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H., & Melief, C. J. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.350 · Cited by 417
Self-citationKenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Löwik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Drijfhout, J. W., Wafelman, A. R., Oostendorp, J., Fleuren, G. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1881 · Cited by 315
Self-citationEvolving immunosuppressive microenvironment during human cervical carcinogenesis
Kobayashi, A., Weinberg, V, Darragh, T., & Smith-McCune, K. (2008) · Mucosal Immunology · doi:10.1038/mi.2008.33 · Cited by 136
Clements, A., Johnston, K., Mazzarelli, J. M., Ricciardi, R. P., & Marmorstein, R. (2000) · Biochemistry · doi:10.1021/bi002111g · Cited by 38
Metadata
- Authors
- Ressing, M. E., van Driel, W. J., Brandt, R. M. P., Kenter, G. G., de Jong, J. H., Bauknecht, T., Fleuren, G.-J., Hoogerhout, P., Offringa, R., Sette, A., Celis, E., Grey, H., Trimbos, B. J., Kast, W. M., & Melief, C. J. M.
- Venue
- Journal of Immunotherapy
- Published
- 2000-03
- Volume
- 23
- Issue
- 2
- Pages
- 255-266
- ISSN
- 1524-9557 (ISSN-L)
- OpenAlex
- W2072461945
- Cited by
- 168
- References
- 3
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients With Cervical Carcinoma. https://app.cochat.ai/papers/10.1097/00002371-200003000-00010
- The paper
- Ressing, M. E., van Driel, W. J., Brandt, R. M. P., Kenter, G. G., de Jong, J. H., Bauknecht, T., Fleuren, G.-J., Hoogerhout, P., Offringa, R., Sette, A., Celis, E., Grey, H., Trimbos, B. J., Kast, W. M., & Melief, C. J. M. (2000). Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients With Cervical Carcinoma. Journal of Immunotherapy. https://doi.org/10.1097/00002371-200003000-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.